ID   CYLD_HUMAN              Reviewed;         956 AA.
AC   Q9NQC7; O94934; Q7L3N6; Q96EH0; Q9NZX9;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 156.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase CYLD;
DE            EC=3.4.19.12 {ECO:0000269|PubMed:18313383};
DE   AltName: Full=Deubiquitinating enzyme CYLD;
DE   AltName: Full=Ubiquitin thioesterase CYLD;
DE   AltName: Full=Ubiquitin-specific-processing protease CYLD;
GN   Name=CYLD {ECO:0000303|PubMed:12917689, ECO:0000312|HGNC:HGNC:2584};
GN   Synonyms=CYLD1, KIAA0849 {ECO:0000303|PubMed:10048485};
GN   ORFNames=HSPC057;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   INVOLVEMENT IN FAMILIAL CYLINDROMATOSIS.
RX   PubMed=10835629; DOI=10.1038/76006;
RA   Bignell G.R., Brown C., Biggs P.J., Lakhani S.R., Jones C., Hansen J.,
RA   Blair E., Hofmann B., Siebert R., Turner G., Evans D.G.,
RA   Schrander-Stumpel C., Beemer F.A., Van Den Ouweland A., Halley D.,
RA   Delpech B., Cleveland M.G., Leigh I., Leisti J., Rasmussen S.,
RA   Wallace M.R., Fenske C., Banerjee P., Oiso N., Chaggar R., Merrett S.,
RA   Leonard N., Huber M., Hohl D., Chapman P., Burn J., Swift S.,
RA   Smith A., Ashworth A., Stratton M.R.;
RT   "Identification of the familial cylindromatosis tumor suppressor
RT   gene.";
RL   Nat. Genet. 25:160-165(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M.,
RA   Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 5:355-364(1998).
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 397-956.
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [6]
RP   FUNCTION, INTERACTION WITH IKBKG/NEMO, AND MUTAGENESIS OF CYS-601.
RX   PubMed=12917689; DOI=10.1038/nature01803;
RA   Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H.,
RA   Ashworth A., Mosialos G.;
RT   "CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB
RT   activation by TNFR family members.";
RL   Nature 424:793-796(2003).
RN   [7]
RP   FUNCTION, INTERACTION WITH IKBKG/NEMO, AND MUTAGENESIS OF CYS-601.
RX   PubMed=12917690; DOI=10.1038/nature01811;
RA   Brummelkamp T.R., Nijman S.M.B., Dirac A.M.G., Bernards R.;
RT   "Loss of the cylindromatosis tumour suppressor inhibits apoptosis by
RT   activating NF-kappaB.";
RL   Nature 424:797-801(2003).
RN   [8]
RP   FUNCTION, INTERACTION WITH IKBKG/NEMO AND TRAF2, AND MUTAGENESIS OF
RP   SER-457 AND HIS-871.
RX   PubMed=12917691; DOI=10.1038/nature01802;
RA   Kovalenko A., Chable-Bessia C., Cantarella G., Israeel A., Wallach D.,
RA   Courtois G.;
RT   "The tumour suppressor CYLD negatively regulates NF-kappaB signalling
RT   by deubiquitination.";
RL   Nature 424:801-805(2003).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TRIP.
RX   PubMed=14676304; DOI=10.1084/jem.20031187;
RA   Regamey A., Hohl D., Liu J.W., Roger T., Kogerman P., Toftgaard R.,
RA   Huber M.;
RT   "The tumor suppressor CYLD interacts with TRIP and regulates
RT   negatively nuclear factor kappaB activation by tumor necrosis
RT   factor.";
RL   J. Exp. Med. 198:1959-1964(2003).
RN   [10]
RP   FUNCTION, INTERACTION WITH TRAF2, ENZYME REGULATION, MUTAGENESIS OF
RP   SER-418; SER-422; SER-432; SER-436; SER-439; SER-441 AND SER-444, AND
RP   PHOSPHORYLATION AT SER-418.
RX   PubMed=15870263; DOI=10.1128/MCB.25.10.3886-3895.2005;
RA   Reiley W., Zhang M., Wu X., Granger E., Sun S.C.;
RT   "Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase
RT   gamma-dependent phosphorylation.";
RL   Mol. Cell. Biol. 25:3886-3895(2005).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF CYS-601, INTERACTION WITH PLK1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17495026; DOI=10.1073/pnas.0703268104;
RA   Stegmeier F., Sowa M.E., Nalepa G., Gygi S.P., Harper J.W.,
RA   Elledge S.J.;
RT   "The tumor suppressor CYLD regulates entry into mitosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8869-8874(2007).
RN   [12]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH DDX58; MAVS; TBK1 AND IKKE.
RX   PubMed=18636086; DOI=10.1038/embor.2008.136;
RA   Friedman C.S., O'Donnell M.A., Legarda-Addison D., Ng A.,
RA   Cardenas W.B., Yount J.S., Moran T.M., Basler C.F., Komuro A.,
RA   Horvath C.M., Xavier R., Ting A.T.;
RT   "The tumour suppressor CYLD is a negative regulator of RIG-I-mediated
RT   antiviral response.";
RL   EMBO Rep. 9:930-936(2008).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18222923; DOI=10.1074/jbc.M708470200;
RA   Gao J., Huo L., Sun X., Liu M., Li D., Dong J.T., Zhou J.;
RT   "The tumor suppressor CYLD regulates microtubule dynamics and plays a
RT   role in cell migration.";
RL   J. Biol. Chem. 283:8802-8809(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20194890; DOI=10.1182/blood-2009-10-248526;
RA   Gao J., Sun L., Huo L., Liu M., Li D., Zhou J.;
RT   "CYLD regulates angiogenesis by mediating vascular endothelial cell
RT   migration.";
RL   Blood 115:4130-4137(2010).
RN   [16]
RP   FUNCTION, INTERACTION WITH HDAC6; BCL3 AND MICROTUBULES, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19893491; DOI=10.1038/emboj.2009.317;
RA   Wickstrom S.A., Masoumi K.C., Khochbin S., Fassler R., Massoumi R.;
RT   "CYLD negatively regulates cell-cycle progression by inactivating
RT   HDAC6 and increasing the levels of acetylated tubulin.";
RL   EMBO J. 29:131-144(2010).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH DVL1 AND DVL3.
RX   PubMed=20227366; DOI=10.1016/j.molcel.2010.01.035;
RA   Tauriello D.V., Haegebarth A., Kuper I., Edelmann M.J., Henraat M.,
RA   Canninga-van Dijk M.R., Kessler B.M., Clevers H., Maurice M.M.;
RT   "Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling
RT   through K63-linked ubiquitination of Dvl.";
RL   Mol. Cell 37:607-619(2010).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-418 AND SER-422, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CEP350.
RX   PubMed=25134987; DOI=10.1038/ncomms5585;
RA   Eguether T., Ermolaeva M.A., Zhao Y., Bonnet M.C., Jain A.,
RA   Pasparakis M., Courtois G., Tassin A.M.;
RT   "The deubiquitinating enzyme CYLD controls apical docking of basal
RT   bodies in ciliated epithelial cells.";
RL   Nat. Commun. 5:4585-4585(2014).
RN   [21]
RP   INVOLVEMENT IN FCYL, AND INVOLVEMENT IN BRSS.
RX   PubMed=12190880; DOI=10.1046/j.1523-1747.2002.01839.x;
RA   Poblete Gutierrez P., Eggermann T., Hoeller D., Jugert F.K.,
RA   Beermann T., Grussendorf-Conen E.-I., Zerres K., Merk H.F., Frank J.;
RT   "Phenotype diversity in familial cylindromatosis: a frameshift
RT   mutation in the tumor suppressor gene CYLD underlies different tumors
RT   of skin appendages.";
RL   J. Invest. Dermatol. 119:527-531(2002).
RN   [22]
RP   INVOLVEMENT IN BRSS.
RX   PubMed=12950348; DOI=10.1046/j.1365-2230.2003.01344.x;
RA   Scheinfeld N., Hu G., Gill M., Austin C., Celebi J.T.;
RT   "Identification of a recurrent mutation in the CYLD gene in Brooke-
RT   Spiegler syndrome.";
RL   Clin. Exp. Dermatol. 28:539-541(2003).
RN   [23]
RP   INVOLVEMENT IN MFT1.
RX   PubMed=16307661; DOI=10.1111/j.1365-2133.2005.06960.x;
RA   Liang Y.H., Gao M., Sun L.D., Liu L.J., Cui Y., Yang S., Fan X.,
RA   Wang J., Xiao F.L., Zhang X.J.;
RT   "Two novel CYLD gene mutations in Chinese families with
RT   trichoepithelioma and a literature review of 16 families with
RT   trichoepithelioma reported in China.";
RL   Br. J. Dermatol. 153:1213-1215(2005).
RN   [24]
RP   INVOLVEMENT IN BRSS.
RX   PubMed=15854031; DOI=10.1111/j.0022-202X.2005.23688.x;
RA   Bowen S., Gill M., Lee D.A., Fisher G., Geronemus R.G., Vazquez M.E.,
RA   Celebi J.T.;
RT   "Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial
RT   cylindromatosis, and multiple familial trichoepithelioma: lack of
RT   genotype-phenotype correlation.";
RL   J. Invest. Dermatol. 124:919-920(2005).
RN   [25]
RP   INVOLVEMENT IN FCYL, AND INVOLVEMENT IN MFT1.
RX   PubMed=16922728; DOI=10.1111/j.1399-0004.2006.00667.x;
RA   Young A.L., Kellermayer R., Szigeti R., Teszas A., Azmi S.,
RA   Celebi J.T.;
RT   "CYLD mutations underlie Brooke-Spiegler, familial cylindromatosis,
RT   and multiple familial trichoepithelioma syndromes.";
RL   Clin. Genet. 70:246-249(2006).
RN   [26]
RP   FUNCTION.
RX   PubMed=26670046; DOI=10.1016/j.celrep.2015.11.009;
RA   Draber P., Kupka S., Reichert M., Draberova H., Lafont E.,
RA   de Miguel D., Spilgies L., Surinova S., Taraborrelli L., Hartwig T.,
RA   Rieser E., Martino L., Rittinger K., Walczak H.;
RT   "LUBAC-recruited CYLD and A20 regulate gene activation and cell death
RT   by exerting opposing effects on linear ubiquitin in signaling
RT   complexes.";
RL   Cell Rep. 13:2258-2272(2015).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH RNF31.
RX   PubMed=26997266; DOI=10.1016/j.celrep.2016.02.062;
RA   Hrdinka M., Fiil B.K., Zucca M., Leske D., Bagola K., Yabal M.,
RA   Elliott P.R., Damgaard R.B., Komander D., Jost P.J., Gyrd-Hansen M.;
RT   "CYLD limits Lys63- and Met1-linked ubiquitin at receptor complexes to
RT   regulate innate immune signaling.";
RL   Cell Rep. 14:2846-2858(2016).
RN   [28]
RP   STRUCTURE BY NMR OF 460-550, AND INTERACTION WITH IKBKG.
RX   PubMed=15341735; DOI=10.1016/j.str.2004.07.012;
RA   Saito K., Kigawa T., Koshiba S., Sato K., Matsuo Y., Sakamoto A.,
RA   Takagi T., Shirouzu M., Yabuki T., Nunokawa E., Seki E., Matsuda T.,
RA   Aoki M., Miyata Y., Hirakawa N., Inoue M., Terada T., Nagase T.,
RA   Kikuno R., Nakayama M., Ohara O., Tanaka A., Yokoyama S.;
RT   "The CAP-Gly domain of CYLD associates with the proline-rich sequence
RT   in NEMO/IKKgamma.";
RL   Structure 12:1719-1728(2004).
RN   [29]
RP   STRUCTURE BY NMR OF 125-304.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the 1st and 2nd CAP-Gly domains in human
RT   cylindromatosis tumor suppressor CYLD.";
RL   Submitted (NOV-2004) to the PDB data bank.
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 583-956 IN COMPLEX WITH ZINC
RP   IONS, FUNCTION, ACTIVE SITE, MUTAGENESIS OF CYS-601, CATALYTIC
RP   ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=18313383; DOI=10.1016/j.molcel.2007.12.018;
RA   Komander D., Lord C.J., Scheel H., Swift S., Hofmann K., Ashworth A.,
RA   Barford D.;
RT   "The structure of the CYLD USP domain explains its specificity for
RT   Lys63-linked polyubiquitin and reveals a B box module.";
RL   Mol. Cell 29:451-464(2008).
RN   [31]
RP   VARIANT MFT1 GLY-747, AND VARIANT BRSS GLY-747.
RX   PubMed=14632188; DOI=10.1046/j.1523-1747.2003.12514.x;
RA   Hu G., Oender M., Gill M., Aksakal B., Oeztas M., Guerer M.A.,
RA   Celebi J.T.;
RT   "A novel missense mutation in CYLD in a family with Brooke-Spiegler
RT   syndrome.";
RL   J. Invest. Dermatol. 121:732-734(2003).
CC   -!- FUNCTION: Deubiquitinase that specifically cleaves 'Lys-63'-linked
CC       polyubiquitin chains. Has endodeubiquitinase activity. Plays an
CC       important role in the regulation of pathways leading to NF-kappa-B
CC       activation (PubMed:12917689, PubMed:12917691). Contributes to the
CC       regulation of cell survival, proliferation and differentiation via
CC       its effects on NF-kappa-B activation (PubMed:12917690). Negative
CC       regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and
CC       thereby promotes acetylation of alpha-tubulin and stabilization of
CC       microtubules (PubMed:19893491). Plays a role in the regulation of
CC       microtubule dynamics, and thereby contributes to the regulation of
CC       cell proliferation, cell polarization, cell migration, and
CC       angiogenesis (PubMed:18222923, PubMed:20194890). Required for
CC       normal cell cycle progress and normal cytokinesis
CC       (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation
CC       of NF-kappa-B. Plays a role in the regulation of inflammation and
CC       the innate immune response, via its effects on NF-kappa-B
CC       activation (PubMed:18636086). Dispensable for the maturation of
CC       intrathymic natural killer cells, but required for the continued
CC       survival of immature natural killer cells. Negatively regulates
CC       TNFRSF11A signaling and osteoclastogenesis (By similarity).
CC       Involved in the regulation of ciliogenesis, allowing ciliary basal
CC       bodies to migrate and dock to the plasma membrane; this process
CC       does not depend on NF-kappa-B activation (By similarity). Also
CC       able to remove linear ('Met-1'-linked) polyubiquitin chains to
CC       regulate innate immunity: recruited to the LUBAC complex and,
CC       together with OTULIN, restricts linear polyubiquitin formation on
CC       RIPK2 in response to NOD2 stimulation (PubMed:26670046,
CC       PubMed:26997266). {ECO:0000250|UniProtKB:Q80TQ2,
CC       ECO:0000269|PubMed:12917689, ECO:0000269|PubMed:12917690,
CC       ECO:0000269|PubMed:12917691, ECO:0000269|PubMed:14676304,
CC       ECO:0000269|PubMed:17495026, ECO:0000269|PubMed:18222923,
CC       ECO:0000269|PubMed:18636086, ECO:0000269|PubMed:19893491,
CC       ECO:0000269|PubMed:20194890, ECO:0000269|PubMed:20227366,
CC       ECO:0000269|PubMed:26670046, ECO:0000269|PubMed:26997266}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC       {ECO:0000269|PubMed:18313383}.
CC   -!- ENZYME REGULATION: Inhibited by phosphorylation at serine
CC       residues. {ECO:0000269|PubMed:15870263}.
CC   -!- SUBUNIT: Interacts (via CAP-Gly domain) with IKBKG/NEMO (via
CC       proline-rich C-terminal region). Interacts with TRAF2 and TRIP.
CC       Interacts with PLK1, DVL1, DVL3, MAVS, TBK1, IKKE and DDX58.
CC       Interacts (via CAP-Gly domain) with microtubules. Interacts with
CC       HDAC6 and BCL3. Interacts with SQSTM1 and MAP3K7. Identified in a
CC       complex with TRAF6 and SQSTM1 (By similarity). Interacts with
CC       CEP350 (PubMed:25134987). Interacts with RNF31 (PubMed:26997266).
CC       {ECO:0000250, ECO:0000269|PubMed:25134987,
CC       ECO:0000269|PubMed:26997266}.
CC   -!- INTERACTION:
CC       O95786:DDX58; NbExp=2; IntAct=EBI-2117940, EBI-995350;
CC       Q9UBN7:HDAC6; NbExp=4; IntAct=EBI-2117940, EBI-301697;
CC       Q96J02:ITCH; NbExp=3; IntAct=EBI-2117940, EBI-1564678;
CC       Q96J02-2:ITCH; NbExp=2; IntAct=EBI-2117940, EBI-6672198;
CC       Q71U36:TUBA1A; NbExp=6; IntAct=EBI-2117940, EBI-302552;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, perinuclear region.
CC       Cytoplasm, cytoskeleton. Cell membrane; Peripheral membrane
CC       protein; Cytoplasmic side. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:25134987}.
CC       Cytoplasm, cytoskeleton, spindle {ECO:0000269|PubMed:25134987}.
CC       Cytoplasm, cytoskeleton, cilium basal body
CC       {ECO:0000250|UniProtKB:Q80TQ2}. Note=Detected at the microtubule
CC       cytoskeleton during interphase. Detected at the midbody during
CC       telophase. During metaphase, it remains localized to the
CC       centrosome but is also present along the spindle
CC       (PubMed:25134987). {ECO:0000250|UniProtKB:Q80TQ2,
CC       ECO:0000269|PubMed:25134987}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NQC7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NQC7-2; Sequence=VSP_011277;
CC   -!- TISSUE SPECIFICITY: Detected in fetal brain, testis, and skeletal
CC       muscle, and at a lower level in adult brain, leukocytes, liver,
CC       heart, kidney, spleen, ovary and lung. Isoform 2 is found in all
CC       tissues except kidney. {ECO:0000269|PubMed:10835629}.
CC   -!- PTM: Phosphorylated on several serine residues by IKKA and/or IKKB
CC       in response to immune stimuli. Phosphorylation requires IKBKG.
CC       Phosphorylation abolishes TRAF2 deubiquitination, interferes with
CC       the activation of Jun kinases, and strongly reduces CD40-dependent
CC       gene activation by NF-kappa-B. {ECO:0000269|PubMed:15870263}.
CC   -!- DISEASE: Cylindromatosis, familial (FCYL) [MIM:132700]: A disorder
CC       characterized by multiple skin tumors that develop from skin
CC       appendages, such as hair follicles and sweat glands. Affected
CC       individuals typically develop large numbers of tumors called
CC       cylindromas that arise predominantly in hairy parts of the body
CC       with approximately 90% on the head and neck. In severely affected
CC       individuals, cylindromas may combine into a confluent mass which
CC       may ulcerate or become infected (turban tumor syndrome).
CC       Individuals with familial cylindromatosis occasionally develop
CC       other types of tumors including spiradenomas that begin in sweat
CC       glands, and trichoepitheliomas arising from hair follicles.
CC       {ECO:0000269|PubMed:12190880, ECO:0000269|PubMed:16922728}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Multiple familial trichoepithelioma 1 (MFT1)
CC       [MIM:601606]: Autosomal dominant dermatosis characterized by the
CC       presence of many skin tumors predominantly on the face. Since
CC       histologic examination shows dermal aggregates of basaloid cells
CC       with connection to or differentiation toward hair follicles, this
CC       disorder has been thought to represent a benign hamartoma of the
CC       pilosebaceous apparatus. Trichoepitheliomas can degenerate into
CC       basal cell carcinoma. {ECO:0000269|PubMed:14632188,
CC       ECO:0000269|PubMed:16307661, ECO:0000269|PubMed:16922728}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Brooke-Spiegler syndrome (BRSS) [MIM:605041]: An
CC       autosomal dominant disorder characterized by the appearance of
CC       multiple skin appendage tumors such as cylindroma,
CC       trichoepithelioma, and spiradenoma. These tumors are typically
CC       located in the head and neck region, appear in early adulthood,
CC       and gradually increase in size and number throughout life.
CC       {ECO:0000269|PubMed:12190880, ECO:0000269|PubMed:12950348,
CC       ECO:0000269|PubMed:14632188, ECO:0000269|PubMed:15854031}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF29029.1; Type=Frameshift; Positions=776, 808, 932; Evidence={ECO:0000305};
CC       Sequence=BAA74872.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CYLDID40232ch16q12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ250014; CAB93533.1; -; mRNA.
DR   EMBL; AB020656; BAA74872.2; ALT_INIT; mRNA.
DR   EMBL; BC012342; AAH12342.1; -; mRNA.
DR   EMBL; AF161542; AAF29029.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS42164.1; -. [Q9NQC7-2]
DR   CCDS; CCDS45482.1; -. [Q9NQC7-1]
DR   RefSeq; NP_001035814.1; NM_001042355.1. [Q9NQC7-2]
DR   RefSeq; NP_001035877.1; NM_001042412.1. [Q9NQC7-2]
DR   RefSeq; NP_056062.1; NM_015247.2. [Q9NQC7-1]
DR   RefSeq; XP_005255869.1; XM_005255812.2. [Q9NQC7-2]
DR   RefSeq; XP_006721212.1; XM_006721149.1. [Q9NQC7-2]
DR   RefSeq; XP_011521209.1; XM_011522907.2. [Q9NQC7-2]
DR   RefSeq; XP_016878466.1; XM_017022977.1. [Q9NQC7-2]
DR   RefSeq; XP_016878467.1; XM_017022978.1. [Q9NQC7-2]
DR   RefSeq; XP_016878468.1; XM_017022979.1. [Q9NQC7-2]
DR   RefSeq; XP_016878469.1; XM_017022980.1. [Q9NQC7-2]
DR   UniGene; Hs.578973; -.
DR   PDB; 1IXD; NMR; -; A=460-550.
DR   PDB; 1WHL; NMR; -; A=125-206.
DR   PDB; 1WHM; NMR; -; A=228-304.
DR   PDB; 2VHF; X-ray; 2.80 A; A/B=583-956.
DR   PDBsum; 1IXD; -.
DR   PDBsum; 1WHL; -.
DR   PDBsum; 1WHM; -.
DR   PDBsum; 2VHF; -.
DR   ProteinModelPortal; Q9NQC7; -.
DR   SMR; Q9NQC7; -.
DR   BioGrid; 107920; 64.
DR   IntAct; Q9NQC7; 28.
DR   MINT; MINT-6804518; -.
DR   STRING; 9606.ENSP00000308928; -.
DR   MEROPS; C67.001; -.
DR   iPTMnet; Q9NQC7; -.
DR   PhosphoSitePlus; Q9NQC7; -.
DR   BioMuta; CYLD; -.
DR   DMDM; 51316104; -.
DR   MaxQB; Q9NQC7; -.
DR   PaxDb; Q9NQC7; -.
DR   PeptideAtlas; Q9NQC7; -.
DR   PRIDE; Q9NQC7; -.
DR   Ensembl; ENST00000311559; ENSP00000308928; ENSG00000083799. [Q9NQC7-1]
DR   Ensembl; ENST00000398568; ENSP00000381574; ENSG00000083799. [Q9NQC7-2]
DR   Ensembl; ENST00000427738; ENSP00000392025; ENSG00000083799. [Q9NQC7-1]
DR   Ensembl; ENST00000564326; ENSP00000454515; ENSG00000083799. [Q9NQC7-2]
DR   Ensembl; ENST00000569418; ENSP00000457576; ENSG00000083799. [Q9NQC7-2]
DR   GeneID; 1540; -.
DR   KEGG; hsa:1540; -.
DR   UCSC; uc002egq.2; human. [Q9NQC7-1]
DR   CTD; 1540; -.
DR   DisGeNET; 1540; -.
DR   GeneCards; CYLD; -.
DR   HGNC; HGNC:2584; CYLD.
DR   HPA; CAB011713; -.
DR   HPA; HPA050095; -.
DR   MalaCards; CYLD; -.
DR   MIM; 132700; phenotype.
DR   MIM; 601606; phenotype.
DR   MIM; 605018; gene.
DR   MIM; 605041; phenotype.
DR   neXtProt; NX_Q9NQC7; -.
DR   OpenTargets; ENSG00000083799; -.
DR   Orphanet; 211; Familial cylindromatosis.
DR   Orphanet; 867; Familial multiple trichoepithelioma.
DR   PharmGKB; PA27084; -.
DR   eggNOG; KOG3556; Eukaryota.
DR   eggNOG; ENOG410XP6I; LUCA.
DR   GeneTree; ENSGT00390000018123; -.
DR   HOGENOM; HOG000006796; -.
DR   HOVERGEN; HBG051281; -.
DR   InParanoid; Q9NQC7; -.
DR   KO; K08601; -.
DR   OMA; CTDGTFK; -.
DR   OrthoDB; EOG091G015D; -.
DR   PhylomeDB; Q9NQC7; -.
DR   TreeFam; TF318734; -.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-936440; Negative regulators of RIG-I/MDA5 signaling.
DR   SIGNOR; Q9NQC7; -.
DR   ChiTaRS; CYLD; human.
DR   EvolutionaryTrace; Q9NQC7; -.
DR   GeneWiki; CYLD_(gene); -.
DR   GenomeRNAi; 1540; -.
DR   PRO; PR:Q9NQC7; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000083799; -.
DR   CleanEx; HS_CYLD; -.
DR   ExpressionAtlas; Q9NQC7; baseline and differential.
DR   Genevisible; Q9NQC7; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; ISS:UniProtKB.
DR   GO; GO:0097542; C:ciliary tip; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:1990380; F:Lys48-specific deubiquitinase activity; IEA:Ensembl.
DR   GO; GO:0061578; F:Lys63-specific deubiquitinase activity; IDA:UniProtKB.
DR   GO; GO:0070064; F:proline-rich region binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; TAS:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0048872; P:homeostasis of number of cells; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0070266; P:necroptotic process; IBA:GO_Central.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0042347; P:negative regulation of NF-kappaB import into nucleus; IDA:UniProtKB.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045581; P:negative regulation of T cell differentiation; IEA:Ensembl.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:1903829; P:positive regulation of cellular protein localization; IEA:Ensembl.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; IEA:Ensembl.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0070536; P:protein K63-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:1990108; P:protein linear deubiquitination; IDA:UniProtKB.
DR   GO; GO:0045577; P:regulation of B cell differentiation; IEA:Ensembl.
DR   GO; GO:1902017; P:regulation of cilium assembly; ISS:UniProtKB.
DR   GO; GO:2001242; P:regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:1901026; P:ripoptosome assembly involved in necroptotic process; IEA:Ensembl.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   Gene3D; 2.30.30.190; -; 3.
DR   InterPro; IPR000938; CAP-Gly_domain.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF01302; CAP_GLY; 2.
DR   Pfam; PF00443; UCH; 1.
DR   SMART; SM01052; CAP_GLY; 3.
DR   SUPFAM; SSF74924; SSF74924; 3.
DR   PROSITE; PS00845; CAP_GLY_1; 1.
DR   PROSITE; PS50245; CAP_GLY_2; 2.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell membrane;
KW   Cell projection; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Disease mutation; Hydrolase; Immunity; Innate immunity; Membrane;
KW   Metal-binding; Microtubule; Phosphoprotein; Protease;
KW   Reference proteome; Repeat; Thiol protease; Tumor suppressor;
KW   Ubl conjugation pathway; Wnt signaling pathway; Zinc.
FT   CHAIN         1    956       Ubiquitin carboxyl-terminal hydrolase
FT                                CYLD.
FT                                /FTId=PRO_0000080698.
FT   DOMAIN      153    198       CAP-Gly 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00045}.
FT   DOMAIN      253    286       CAP-Gly 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00045}.
FT   DOMAIN      492    535       CAP-Gly 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00045}.
FT   DOMAIN      592    950       USP.
FT   REGION      106    593       Interaction with TRIP.
FT                                {ECO:0000269|PubMed:14676304}.
FT   REGION      394    469       Interaction with TRAF2.
FT   REGION      470    554       Interaction with IKBKG/NEMO.
FT                                {ECO:0000269|PubMed:15341735}.
FT   ACT_SITE    601    601       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092,
FT                                ECO:0000269|PubMed:18313383}.
FT   ACT_SITE    871    871       Proton acceptor.
FT                                {ECO:0000305|PubMed:18313383}.
FT   METAL       788    788       Zinc 1.
FT   METAL       791    791       Zinc 1.
FT   METAL       799    799       Zinc 2.
FT   METAL       802    802       Zinc 2.
FT   METAL       817    817       Zinc 1.
FT   METAL       820    820       Zinc 1.
FT   METAL       825    825       Zinc 2.
FT   METAL       833    833       Zinc 2.
FT   MOD_RES     387    387       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     418    418       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:15870263}.
FT   MOD_RES     422    422       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     305    307       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10048485,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011277.
FT   VARIANT     747    747       E -> G (in MFT1 and BRSS;
FT                                dbSNP:rs121908389).
FT                                {ECO:0000269|PubMed:14632188}.
FT                                /FTId=VAR_045967.
FT   MUTAGEN     418    418       S->A: Reduced phosphorylation; when
FT                                associated with A-422; A-432 and A-436.
FT                                Loss of phosphorylation; when associated
FT                                with A-422; A-432; A-436; A-439; A-441
FT                                and A-444. {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     418    418       S->E: Abolishes deubiquitination of
FT                                TRAF2; when associated with E-422; E-432;
FT                                E-436; E-439; E-441 and E-444.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     422    422       S->A: Reduced phosphorylation; when
FT                                associated with A-418; A-432 and A-436.
FT                                Loss of phosphorylation; when associated
FT                                with A-418; A-432; A-436; A-439; A-441
FT                                and A-444. {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     422    422       S->E: Abolishes deubiquitination of
FT                                TRAF2; when associated with E-418; E-432;
FT                                E-436; E-439; E-441 and E-444.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     432    432       S->A: Slightly reduced phosphorylation;
FT                                when associated with A-436. Reduced
FT                                phosphorylation; when associated with A-
FT                                418; A-422 and A-436. Loss of
FT                                phosphorylation; when associated with A-
FT                                418; A-422; A-436; A-439; A-441 and A-
FT                                444. {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     432    432       S->E: Abolishes deubiquitination of
FT                                TRAF2; when associated with E-418; E-422;
FT                                E-436; E-439; E-441 and E-444.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     436    436       S->A: Slightly reduced phosphorylation;
FT                                when associated with A-432. Reduced
FT                                phosphorylation; when associated with A-
FT                                418; A-422 and A-432. Loss of
FT                                phosphorylation; when associated with A-
FT                                418; A-422; A-432; A-439; A-441 and A-
FT                                444. {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     436    436       S->E: Abolishes deubiquitination of
FT                                TRAF2; when associated with E-418; E-422;
FT                                E-432; E-439; E-441 and E-444.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     439    439       S->A: Loss of phosphorylation; when
FT                                associated with A-418; A-422; A-432; A-
FT                                436; A-441 and A-444.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     439    439       S->E: Abolishes deubiquitination of
FT                                TRAF2; when associated with E-418; E-422;
FT                                E-432; E-436; E-441 and E-444.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     441    441       S->A: Loss of phosphorylation; when
FT                                associated with A-418; A-422; A-432; A-
FT                                436; A-439 and A-444.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     441    441       S->E: Abolishes deubiquitination of
FT                                TRAF2; when associated with E-418; E-422;
FT                                E-432; E-436; E-439 and E-444.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     444    444       S->A: Loss of phosphorylation; when
FT                                associated with A-418; A-422; A-432; A-
FT                                436; A-439 and A-441.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     444    444       S->E: Abolishes deubiquitination of
FT                                TRAF2; when associated with E-418; E-422;
FT                                E-432; E-436; E-439 and E-441.
FT                                {ECO:0000269|PubMed:15870263}.
FT   MUTAGEN     457    457       S->A: Abolishes binding to TRAF2.
FT                                {ECO:0000269|PubMed:12917691}.
FT   MUTAGEN     601    601       C->A,S: Loss of deubiquitinating
FT                                activity. {ECO:0000269|PubMed:12917689,
FT                                ECO:0000269|PubMed:12917690,
FT                                ECO:0000269|PubMed:17495026,
FT                                ECO:0000269|PubMed:18313383}.
FT   MUTAGEN     871    871       H->N: Loss of deubiquitinating activity.
FT                                {ECO:0000269|PubMed:12917691}.
FT   STRAND      130    134       {ECO:0000244|PDB:1WHL}.
FT   STRAND      136    139       {ECO:0000244|PDB:1WHL}.
FT   STRAND      141    149       {ECO:0000244|PDB:1WHL}.
FT   STRAND      154    157       {ECO:0000244|PDB:1WHL}.
FT   STRAND      163    167       {ECO:0000244|PDB:1WHL}.
FT   STRAND      169    171       {ECO:0000244|PDB:1WHL}.
FT   TURN        191    193       {ECO:0000244|PDB:1WHL}.
FT   STRAND      194    197       {ECO:0000244|PDB:1WHL}.
FT   HELIX       199    201       {ECO:0000244|PDB:1WHL}.
FT   STRAND      202    204       {ECO:0000244|PDB:1WHL}.
FT   STRAND      235    240       {ECO:0000244|PDB:1WHM}.
FT   STRAND      243    253       {ECO:0000244|PDB:1WHM}.
FT   TURN        259    261       {ECO:0000244|PDB:1WHM}.
FT   STRAND      264    272       {ECO:0000244|PDB:1WHM}.
FT   STRAND      278    280       {ECO:0000244|PDB:1WHM}.
FT   STRAND      283    285       {ECO:0000244|PDB:1WHM}.
FT   STRAND      293    298       {ECO:0000244|PDB:1WHM}.
FT   HELIX       299    301       {ECO:0000244|PDB:1WHM}.
FT   STRAND      302    304       {ECO:0000244|PDB:1WHM}.
FT   TURN        463    465       {ECO:0000244|PDB:1IXD}.
FT   STRAND      466    468       {ECO:0000244|PDB:1IXD}.
FT   STRAND      474    478       {ECO:0000244|PDB:1IXD}.
FT   STRAND      480    482       {ECO:0000244|PDB:1IXD}.
FT   STRAND      486    492       {ECO:0000244|PDB:1IXD}.
FT   STRAND      495    497       {ECO:0000244|PDB:1IXD}.
FT   STRAND      501    508       {ECO:0000244|PDB:1IXD}.
FT   STRAND      514    518       {ECO:0000244|PDB:1IXD}.
FT   STRAND      531    535       {ECO:0000244|PDB:1IXD}.
FT   HELIX       536    538       {ECO:0000244|PDB:1IXD}.
FT   STRAND      539    541       {ECO:0000244|PDB:1IXD}.
FT   HELIX       584    586       {ECO:0000244|PDB:2VHF}.
FT   STRAND      588    591       {ECO:0000244|PDB:2VHF}.
FT   HELIX       601    611       {ECO:0000244|PDB:2VHF}.
FT   STRAND      612    614       {ECO:0000244|PDB:2VHF}.
FT   HELIX       615    617       {ECO:0000244|PDB:2VHF}.
FT   HELIX       618    622       {ECO:0000244|PDB:2VHF}.
FT   HELIX       633    642       {ECO:0000244|PDB:2VHF}.
FT   HELIX       645    650       {ECO:0000244|PDB:2VHF}.
FT   STRAND      652    654       {ECO:0000244|PDB:2VHF}.
FT   HELIX       656    669       {ECO:0000244|PDB:2VHF}.
FT   HELIX       682    690       {ECO:0000244|PDB:2VHF}.
FT   TURN        691    694       {ECO:0000244|PDB:2VHF}.
FT   STRAND      699    704       {ECO:0000244|PDB:2VHF}.
FT   STRAND      710    713       {ECO:0000244|PDB:2VHF}.
FT   HELIX       730    741       {ECO:0000244|PDB:2VHF}.
FT   STRAND      743    747       {ECO:0000244|PDB:2VHF}.
FT   STRAND      750    755       {ECO:0000244|PDB:2VHF}.
FT   STRAND      760    764       {ECO:0000244|PDB:2VHF}.
FT   STRAND      773    775       {ECO:0000244|PDB:2VHF}.
FT   HELIX       778    780       {ECO:0000244|PDB:2VHF}.
FT   STRAND      781    784       {ECO:0000244|PDB:2VHF}.
FT   TURN        789    791       {ECO:0000244|PDB:2VHF}.
FT   HELIX       800    802       {ECO:0000244|PDB:2VHF}.
FT   TURN        806    811       {ECO:0000244|PDB:2VHF}.
FT   HELIX       818    824       {ECO:0000244|PDB:2VHF}.
FT   HELIX       828    830       {ECO:0000244|PDB:2VHF}.
FT   HELIX       844    846       {ECO:0000244|PDB:2VHF}.
FT   STRAND      859    868       {ECO:0000244|PDB:2VHF}.
FT   STRAND      871    877       {ECO:0000244|PDB:2VHF}.
FT   STRAND      879    881       {ECO:0000244|PDB:2VHF}.
FT   STRAND      885    889       {ECO:0000244|PDB:2VHF}.
FT   STRAND      905    908       {ECO:0000244|PDB:2VHF}.
FT   HELIX       911    914       {ECO:0000244|PDB:2VHF}.
FT   HELIX       920    925       {ECO:0000244|PDB:2VHF}.
FT   HELIX       928    930       {ECO:0000244|PDB:2VHF}.
FT   HELIX       935    940       {ECO:0000244|PDB:2VHF}.
FT   STRAND      944    948       {ECO:0000244|PDB:2VHF}.
FT   HELIX       950    952       {ECO:0000244|PDB:2VHF}.
SQ   SEQUENCE   956 AA;  107316 MW;  01831F9A83424631 CRC64;
     MSSGLWSQEK VTSPYWEERI FYLLLQECSV TDKQTQKLLK VPKGSIGQYI QDRSVGHSRI
     PSAKGKKNQI GLKILEQPHA VLFVDEKDVV EINEKFTELL LAITNCEERF SLFKNRNRLS
     KGLQIDVGCP VKVQLRSGEE KFPGVVRFRG PLLAERTVSG IFFGVELLEE GRGQGFTDGV
     YQGKQLFQCD EDCGVFVALD KLELIEDDDT ALESDYAGPG DTMQVELPPL EINSRVSLKV
     GETIESGTVI FCDVLPGKES LGYFVGVDMD NPIGNWDGRF DGVQLCSFAC VESTILLHIN
     DIIPALSESV TQERRPPKLA FMSRGVGDKG SSSHNKPKAT GSTSDPGNRN RSELFYTLNG
     SSVDSQPQSK SKNTWYIDEV AEDPAKSLTE ISTDFDRSSP PLQPPPVNSL TTENRFHSLP
     FSLTKMPNTN GSIGHSPLSL SAQSVMEELN TAPVQESPPL AMPPGNSHGL EVGSLAEVKE
     NPPFYGVIRW IGQPPGLNEV LAGLELEDEC AGCTDGTFRG TRYFTCALKK ALFVKLKSCR
     PDSRFASLQP VSNQIERCNS LAFGGYLSEV VEENTPPKME KEGLEIMIGK KKGIQGHYNS
     CYLDSTLFCL FAFSSVLDTV LLRPKEKNDV EYYSETQELL RTEIVNPLRI YGYVCATKIM
     KLRKILEKVE AASGFTSEEK DPEEFLNILF HHILRVEPLL KIRSAGQKVQ DCYFYQIFME
     KNEKVGVPTI QQLLEWSFIN SNLKFAEAPS CLIIQMPRFG KDFKLFKKIF PSLELNITDL
     LEDTPRQCRI CGGLAMYECR ECYDDPDISA GKIKQFCKTC NTQVHLHPKR LNHKYNPVSL
     PKDLPDWDWR HGCIPCQNME LFAVLCIETS HYVAFVKYGK DDSAWLFFDS MADRDGGQNG
     FNIPQVTPCP EVGEYLKMSL EDLHSLDSRR IQGCARRLLC DAYMCMYQSP TMSLYK
//
